恩替卡韦治疗慢性乙型肝炎的早期临床观察  

Clinical Observation about Entecavir in Treating Chronic Hepatitis B at the Initial Stage.

作　　者：罗玮敏[1] 张迎春[1] 刘中景[1] 

机构地区：[1]青岛市传染病医院,山东青岛266033

出　　处：《临床肝胆病杂志》2008年第1期26-28,共3页Journal of Clinical Hepatology

摘　　要：目的评价恩替卡韦抗病毒治疗慢性乙型肝炎(CHB)24周的疗效和安全性。方法70例CHB患者分为治疗组和对照组。治疗组(30例)予恩替卡韦0.5mg口服,每日一次。对照组(40例)予干扰素α-2b 3MU,肌肉注射,隔日一次。结果治疗组治疗8周时HBV DNA水平较治疗前显著下降;治疗12周,HBVDNA阴转率为26.7%、HBeAg阴转率为33.3%,显著优于对照组,表现出较高的抗病毒早期应答率;治疗24周,HBVDNA阴转率为56.7%、HBeAg阴转率为73.3%,与对照组比较及治疗组自身比较差异显著,肝功能复常率为100%,提示有较良好的维持应答反应。治疗过程中未发生与观察药物相关的严重不良反应。结论恩替卡韦能快速、强效地抑制乙肝病毒复制,安全性和耐受性良好。Objective To evaluate the 24 - week therapeutic effects and safety, of anti - virus therapy of entecavir in patients with chronic hepatitis B （CHB）. Method 70 CHB cases were divided into the treatment group and the control group. Patients were given with entecarvir（0. 5mg po qd） in the treatment group, while the others were given interferon α -2b（300MU im qod） in the control group. Result In the treatment group, the level of serum HBV DNA was obviously decreased than that before treatment at the 8^th week. At the 12^th week the ratio of negative transformation of HBV DNA and HBeAg were separately 26. 7% and 33. 3%, which was superior to the control group; the ratio of recovery of liver function was 90%. There was higher ratio of early response of anti - virus therapy. At the 24^th week, the ratio of negative transformation of HBV DNA and HBeAg were separately 56. 7% and 73.3%, which was superior to the control group and before treatment; the ratio of recovery of liver function was 100%. There was no serious adverse event related with entecavir. Conclusion Entecavir can inhibit the replication of hepatitis B virus and have good safety and tolerance.

关 键 词：慢性乙型肝炎 恩替卡韦 干扰素Α-2B 

分 类 号：R512.6[医药卫生—内科学]